INKT vs. SRZN, TARA, ACHL, PLUR, NKGN, CRTX, ESLA, SABS, BCLI, and QNCX
Should you be buying MiNK Therapeutics stock or one of its competitors? The main competitors of MiNK Therapeutics include Surrozen (SRZN), Protara Therapeutics (TARA), Achilles Therapeutics (ACHL), Pluri (PLUR), NKGen Biotech (NKGN), Cortexyme (CRTX), Estrella Immunopharma (ESLA), SAB Biotherapeutics (SABS), Brainstorm Cell Therapeutics (BCLI), and Quince Therapeutics (QNCX). These companies are all part of the "medical" sector.
MiNK Therapeutics (NASDAQ:INKT) and Surrozen (NASDAQ:SRZN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, community ranking, risk, analyst recommendations, valuation, earnings and institutional ownership.
MiNK Therapeutics' return on equity of 0.00% beat Surrozen's return on equity.
MiNK Therapeutics presently has a consensus target price of $9.00, suggesting a potential upside of 791.09%. Given MiNK Therapeutics' higher probable upside, equities analysts plainly believe MiNK Therapeutics is more favorable than Surrozen.
MiNK Therapeutics has higher earnings, but lower revenue than Surrozen.
MiNK Therapeutics received 8 more outperform votes than Surrozen when rated by MarketBeat users. Likewise, 68.75% of users gave MiNK Therapeutics an outperform vote while only 16.67% of users gave Surrozen an outperform vote.
2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 66.6% of Surrozen shares are owned by institutional investors. 17.8% of MiNK Therapeutics shares are owned by company insiders. Comparatively, 43.5% of Surrozen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
MiNK Therapeutics has a beta of 0.04, suggesting that its share price is 96% less volatile than the S&P 500. Comparatively, Surrozen has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500.
In the previous week, MiNK Therapeutics had 11 more articles in the media than Surrozen. MarketBeat recorded 12 mentions for MiNK Therapeutics and 1 mentions for Surrozen. MiNK Therapeutics' average media sentiment score of 0.57 beat Surrozen's score of 0.00 indicating that MiNK Therapeutics is being referred to more favorably in the media.
Summary
MiNK Therapeutics beats Surrozen on 8 of the 13 factors compared between the two stocks.
Get MiNK Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for INKT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MiNK Therapeutics Competitors List
Related Companies and Tools
